misleading statements

REGENXBIO faces class action over alleged misleading statements about RGX-111 gene therapy. Investors who bought stock between February 2022 and January 2026 may seek compensation.

Enphase Energy faces class action lawsuit over alleged misstatements on inventory management and tax credit impacts. Lead plaintiff deadline: April 20, 2026.

Class action lawsuit alleges BellRing made false statements about sales performance, concealing inventory hoarding as genuine demand. Stock crashed 51.6% total.

PomDoctor faces class action lawsuit alleging securities fraud through social media manipulation, insider stock dumping via offshore accounts, and artificial price inflation. Lead plaintiff deadline: April 6, 2026.

Class action lawsuit filed against $VTGN alleging securities fraud over fasedienol drug trial statements and concealed adverse clinical data.

Law firm sues China Liberal Education Holdings for failing to disclose pump-and-dump manipulation and non-bona fide transactions, harming investors.

Securities class action filed against $MREO for allegedly misleading investors about Phase 3 clinical trial results. Lead plaintiff deadline April 6, 2026.

Class action lawsuit filed against Vistagen Therapeutics after Phase 3 trial failure causes 80% stock plunge. Investors have until March 16, 2026 deadline.

Robbins LLP sues Mereo BioPharma over setrusumab trial failures; stock crashes 87.7% to $0.29 after December 29 announcement.

Richtech Robotics faces securities lawsuit after Microsoft denied commercial partnership claimed in January press release. Stock surged 30% then fell 20% following the clarification.

Class action lawsuit filed against $INO for allegedly false statements about INO-3107 treatment and CELLECTRA device. Lead plaintiff deadline is April 7, 2026.

Class action lawsuit filed against $UGDX alleging false statements about setrusumab efficacy for Osteogenesis Imperfecta, claiming Phase III results overstated drug benefits.

Class action lawsuit filed against Richtech Robotics for falsely claiming commercial partnership with Microsoft's AI Co-Innovation Labs, triggering sharp stock decline.

Plug Power faces securities fraud lawsuit over allegedly false DOE loan claims. PLUG shareholders have until April 3, 2026 to file in class action.

Varonis faces class action lawsuit over undisclosed business challenges. Stock crashed 48.7% after disappointing guidance. Investors must act by March 9, 2026.

Varonis faces class action for allegedly misrepresenting ARR growth sustainability, triggering 48.7% stock collapse. Lead plaintiff deadline: March 9, 2026.

Pomerantz files class action against Inovio Pharmaceuticals for alleged securities fraud related to false FDA approval statements and concealed manufacturing deficiencies.

Franklin BSP Realty Trust faces class action lawsuit alleging securities fraud after disclosing delayed property sales and excess dividend distributions. Stock plunged 14.2%.

Rosen Law Firm urges $METC investors to join securities class action alleging false statements about mining operations. Lead plaintiff deadline: March 31, 2026.

Law firm files securities lawsuit against $CORT alleging false statements about FDA interactions regarding relacorilant drug approval prospects.